US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Elicera publishes annual report for 2025

Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, today announced that the Annual Report for 2025 has been published.     Elicera Therapeutic’s annual report is available at the home.page.   Annual meeting will take place 25 June kl 13.00 at Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm, Sweden).   This press release has been

Elicera announces outcome of the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES. SEE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASEElicera Therapeutics AB (publ) ("Elicera" or the "Company") announces the outcome of the partially guaranteed rights issue of

Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved

Gothenburg, May 25, 2026 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, today announced that the Company has now received approval for the final reporting to the European Innovation Council Accelerator Programme for the CARMA study, and that a final payment has also been approved.The final payment amounts to approximately EUR 130,000, bringing the total amount

Elicera publishes information document regarding the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES. SEE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.The Board of Directors of Elicera Therapeutics AB (publ) (“Elicera” or the “Company”) publishes information document in

Elicera Therapeutics carries out a rights issue of approximately SEK 73 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES. SEE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASEElicera Therapeutics AB (publ) (“Elicera” or the “Company”) hereby announces that the Board of Directors has

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2026

First quarter (January-March 2026) · Operating profit/loss amounted to SEK -5,116,779 (-8,069,404). · Loss for the period amounted to SEK -5,060,060 (-8,013,462). · Cash flow from operating activities totaled SEK -6,982,412 (-744,924). · Earnings per share before and after dilution totaled SEK -0.10 (-0.22)   Key events during the quarter · Elicera announces final data from its Phase I/IIa trial of oncolytic virus ELC-100 in neuroendocrine tumors, demonstrating a favorable safety profile and promising · efficacy signals. · Elicera provides update on

Elicera Therapeutics Announces Swedish Cancer Society’s Senior Investigator Award to Chief Development Officer Di Yu

Gothenburg, March 20, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, is pleased to announce that its Chief Development Officer and co-founder, Di Yu, has been awarded the prestigious Senior Investigator Award from the Swedish Cancer Society (Cancerfonden).The award provides a research grant of SEK 3,885,000, distributed over 3 years. This funding supports

Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate

Gothenburg, March 11, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, today announced that it has received a Notice of Allowance from the Japan Patent Office regarding its patent application for the CAR T-cell candidate ELC-401.Once the patent has been granted, it can be maintained in force until 2041.The patent protects Elicera's special antibodies that

Elicera Therapeutics’ Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)

Gothenburg, March 10, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, congratulates its Chief Scientific Officer, Professor Magnus Essand, who has been named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden). The award is given in recognition of his groundbreaking and world-unique research in immunotherapy, where, through advanced

Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients

Gothenburg, March 6, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, today provides an update on the ongoing Phase I/IIa CARMA study evaluating its lead CAR T-cell therapy candidate ELC-301 in patients with relapsed or refractory B-cell lymphoma. New data shows complete metabolic responses from the first two patients treated in cohort 3 (the highest dose level to

Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway

Gothenburg, February 27, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today provides an update on the development of its iTANK-armed CAR T-cell therapy candidate ELC-401 for the treatment of recurrent glioblastoma, an aggressive form of brain cancer with significant unmet medical need.ELC-401 is an iTANK-armed CAR T-cell therapy targeting the tumor antigen IL13Ra2, which is overexpressed in most glioblastoma tumors. The program leverages Elicera's iTANK technology

Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference

Gothenburg, February 18, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today announces that updated clinical data from the ongoing Phase I/IIa CARMA study with its lead CAR T-cell therapy candidate ELC-301 will be presented on March 6, 2026 at the 10th Zurich Immuno-Oncology Conference 2026 in Zürich, Switzerland.The update will be presented by the Company’s Chief Scientific Officer, Professor Magnus Essand, during an invited scientific presentation at the 10th

Elicera Therapeutics AB (publ) Year-End 1 January – 31 December 2025

Fourth quarter (October-December 2025) · Operating loss amounted to o SEK -7,129,626 (-2,911,958). · Loss for the period amounted to SEK -6,965,286 (-2,603,242). · Cash flow from operating activities totaled SEK -10,076,983 (-4,232,090). · Earnings per share before and after dilution totaled SEK -0.14 (-0.07). · Proposed dividend of SEK 0.00 per share (0.00 for the preceding year).   Period (January-December 2025) · Operating loss amounted to SEK -17,944,682 (-16,884,056). · Loss for the period amounted to SEK -17,406,665 (-16,110,327). · Cash flow from

Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study

Gothenburg, February 11, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today announces that an abstract presenting data from the ongoing Phase I/IIa CARMA study has been accepted for presentation at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting in Dublin, Ireland, taking place May 6–9, 2026. The poster presentation will highlight complete metabolic response in four of six patients treated with the iTANK-armed CAR T-cell therapy ELC-301 in

Elicera Therapeutics’ CSO invited to present at multiple scientific conferences

Gothenburg, January 22, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary and commercially available technology platform iTANK, announces that the company’s Chief Scientific Officer, professor Magnus Essand, has been invited to hold presentations on CAR T-cells and the iTANK-platform at multiple scientific conferences.EBMT-EHA 8th European CAR T-cell Meeting, 12-14 February 2026Palma de Mallorca, SpainTitle of presentation: NAP

Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors

Gothenburg, January 9, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announces final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases. The study demonstrates that ELC-100, was generally well-tolerated with no dose-limiting toxicities observed. Importantly, the

Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Correction: The press release published on October 23, 2025 at 16:01 regarding the change of Certified Adviser and Liquidity Provider stated that the change of Liquidity Provider was scheduled for February 2, 2026. The corrected date for the change of Liquidity Provider is January 22, 2026. That date is the only adjustment that’s been made in the original press release below.Elicera Therapeutics AB (publ) hereby announces a change of Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ). Elicera Therapeutics AB (publ) (the “Company”) has entered into an

Elicera Therapeutics AB (publ) Interim 1 January – 30 September 2025

Third quarter (July-September 2025) · Operating loss amounted to SEK 146,689 (-2,697,267). · Loss for the period amounted to SEK 304,153 (-2,514,629). · Cash flow from operating activities totaled SEK -4,738,100 (-4,738,100). · Earnings per share before and after dilution totaled SEK +0.01 (-0.07).   Period (January-September 2025) · Operating loss amounted to SEK -10,815,056 (-13,972,098). · Loss for the period amounted to SEK -10,441,379 (-13,507,085). · Cash flow from operating activities totaled SEK -11,474,233 (-19,231,075). · Earnings per share before

Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research

Gothenburg, November 13, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, announces today that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research.The grant is awarded to Professor Magnus Essand in his role as an employed academic researcher at Uppsala University and forms a

Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Elicera Therapeutics AB (publ) hereby announces a change of Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ).Elicera Therapeutics AB (publ) (the “Company”) has entered into an agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding the roles as Certified Adviser and Liquidity provider. DNB Carnegie will take over as Certified Adviser on December 1, 2025 and Liquidity provider on February 2, 2026. Until the respective dates, Mangold Fondkommission AB will continue to act as the Company's Certified Adviser and Liquidity provider.

Elicera clarifies status of the iTANK-platform patent application in the U.S.

Gothenburg, August 25, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, clarifies today that the ongoing patent application for the company’s iTANK platform in the United States is still under examination by the United States Patent and Trademark Office (USPTO).The Board of Appeals at the United States Patent and Trademark Office (USPTO) issued a decision on

Elicera Therapeutics AB (publ) Interim 1 January – 30 June 2025

Second quarter (April-June 2025) · Operating loss amounted to SEK -2,892,341 (-5,841,409). · Loss for the period amounted to SEK -2,732,070 (-5,622,779). · Cash flow from operating activities totaled SEK -5,991,211 (-7,733,270). · Earnings per share before and after dilution totaled SEK -0.06 (-0.16).   Period (April-June 2025) · Operating loss amounted to SEK -10,961,745 (-11,274,831). · Loss for the period amounted to SEK -10,745,532 (-10,992,456). · Cash flow from operating activities totaled SEK -6,736,135 (-16,997,666). · Earnings per share before and

Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy

Gothenburg, August 25, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, today announces preliminary data from the first two cohorts of the ongoing Phase I/IIa CARMA study with ELC-301. The results, assessed by the principal investigator, show that 4 out of 6 treated patients achieved complete metabolic response (CMR, no active disease). The data will be presented

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media